Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 876 - 900 of 14622 in total
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and ... agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and ... indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the...
Approved
Matched Description: … It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing ... and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. ... A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Approved
Investigational
Matched Description: … Antilipemic agent that lowers cholesterol and triglycerides. ... It decreases low density lipoproteins and increases high density lipoproteins. …
Matched Categories: … Benzamides and benzamide derivatives …
Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. It also concentrates in the thyroid gland, salivary glands, gastric mucosa,...
Approved
Investigational
Matched Description: … It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. ... technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and ... following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and
Matched Categories: … Indicators and Reagents …
Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states . It returns UV filters to their ground states without absorbing sunlight . It is used as a solvent for crystalline UV filters and is easily emulsified and suitable...
Approved
Experimental
Matched Description: … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various ... lotions, creams, sprays, sticks, and gel formulations [F104]. ... It currently enjoys regional approvals in Canada, the EU, and the US [L2847]. …
Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Approved
Experimental
Matched Description: … Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes …
Matched Categories: … Alimentary Tract and Metabolism …
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Description: … bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and
Matched Categories: … Blood and Blood Forming Organs …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Description: … adult use and liquid formulation for pediatric use. ... Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is ... used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria …
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996....
Approved
Vet approved
Matched Description: … The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients ... Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. ... [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition …
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling...
Approved
Investigational
Matched Description: … New Zealand and Canada have also followed suit in recalling the drug. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms...
Approved
Experimental
Matched Description: … Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an ... synthetic pyrethroid used as a pesticide against household pest insects such as mosquitoes, houseflies and
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Description: … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. ... is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and ... This drug was approved after being designed as an orphan drug with a fast track and priority review status …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand ... It is available in oral and opthalmic dosage forms in Japan. ... The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. …
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration ... acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and ... ], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed …
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) in June 2007. ... Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated ... (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. …
Matched Categories: … Modafinil and isomer ... Metabolic Side Effects of Drugs and Substances ... Psychostimulants, Agents Used for ADHD and Nootropics …
Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Approved
Matched Description: … Sagamicin and Luxomicina. ... Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names …
Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.[A39895, A251755] It is a prodrug of baloxavir with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl...
Approved
Investigational
Matched Categories: … Baloxavir and prodrugs …
Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Approved
Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Description: … to form a radical anion, thereby damaging and killing the target pathogen. ... It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays ... improved oral absorption and a longer terminal elimination half-life than other drugs in this class. …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn
Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
Approved
Matched Categories: … Aluminum and magnesium containing antacids …
Displaying drugs 876 - 900 of 14622 in total